BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 16441465)

  • 1. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.